The First Effective Vaccine For "corona" Will Not Be Available Before 2021

"The first Coronavirus vaccine will not be produced before 2021​", and Oxford University​ work very hard to produce it by the end of the year 2020.

A race between several countries to acquire an effective vaccine against the emerging corona virus, talking about dates presented by millions of people has become a primary concern, in addition to the question of which country will get the first dose of it. A report published by the National Interest stated that vaccines may be available sooner than we expect, especially since many of them in Europe and America have reached the third and final phase of trials. The world is looking forward to 3 vaccines that entered the most advanced third stage, as the effectiveness is measured on thousands of volunteers. This applies to the experimental vaccines developed by the German companies Biontech and the American Pfizer, the American laboratories of Moderna and the University of Oxford in cooperation with the British "AstraZeneca".   According to "CNN", the giving of the first dose of the "Moderna" vaccine began on the 28th of the past, and will continue until the end of next September, and will include giving it to 30,000 volunteers. As for the second dose, it will be given starting from the end of this month until the end of next October, 28 days after the first dose. From mid-September to mid-November, a wait will take two weeks, after the second dose, to be effective. In mid-January 2021, the results of the "Moderna" vaccine will be published in the medical journal, and the possibility of publishing it will be discussed later. As for the Oxford University vaccine, clinical trials for the third phase are being conducted in Britain, America, Brazil and South Africa.  In India, trials will begin on the vaccine, which the pharmaceutical company AstraZeneca obtained a license next week, in partnership with the Serum Institute. She said at the end of last July that the vaccine might be ready by the end of the year. As for the vaccine, which is being developed by the German companies Biontech and the American Pfizer, it has reached advanced stages, prompting the United States to contract with them to purchase 100 million doses at the start of production, in a deal amounting to about two billion dollars.

Here are the full details​:Positive news and great efforts that have achieved good results, heralding one or more vaccines to protect humans from the deadly virus «Corona». A report published by the National Interest stated that vaccines may be available sooner than we expect, especially since many vaccines in Europe and America have arrived. To the third and final phase of experiments. Days after Russia announced the acquisition of the "Sputnik V" vaccine, despite the criticism and doubts raised about it, China announced yesterday that it had granted the first patent to "Cansino Biology" company for the "AD5-NCOV" vaccine against "Covid-19". The official People's Daily said that the issuance of the patent took place on the 11th of this month, the same day that Russian President Vladimir Putin announced that the Russian Ministry of Health had approved the Russian vaccine "Sputnik V".​

At the end of last July, the World Health Organization counted 26 candidate vaccines, which are being evaluated during clinical trials on humans, and most of these trials are still in the "first stage" that mainly aims to assess the safety of the product, or the "second stage", when an issue is actually explored. Potency. There are five vaccines in the most advanced "third stage", as the effectiveness is measured on thousands of volunteers, and this applies to the experimental vaccines developed by the German companies "Biontech" and "Pfizer" of the United States, and the American "Moderna" laboratories and the laboratories of "Sinopharma" and "Chinese Sinovac". And the University of Oxford in cooperation with the British "AsraZeneca"t. The University of Oxford said at the end of July that the vaccine may be ready by the end of the year.  Currently, Phase 3 clinical trials are underway in Britain, America, Brazil and South Africa. In India, trials will begin on the vaccine, which the pharmaceutical company, AstraZeneca, obtained a license next week, in partnership with the Serum Institute. Before starting the production of the vaccine, it must be confirmed that it is successful in the last-stage trials, and large quantities should be provided, and the regulatory authorities must quickly approve a license for emergency use. The vaccine developed by the German company "Biontech" and "Pfizer" of the United States has reached advanced stages as well, prompting the United States to contract with them to purchase 100 million doses at the start of production, in a deal amounting to about two billion dollars,  Despite the good data on clinical trials of the vaccine, it is still awaiting the successful completion of phase III trials, which will grant it a license from the Food and Drug Administration at the time. At the end of last month, the US drug development company, Moderna, said it had begun human tests with the US National Institutes of Health. The private "Research Centers of America" ​​organization, located in Hollywood, has tested six vaccines, two of which are in the third phase. Yesterday, MRNE-1273, which was developed in cooperation between Beautique Moderna and the US National Institutes of Health, was tested and reached its third phase, which was launched across the country on July 27th. The United States has invested more than $ 10 billion so far in six vaccine projects and signed contracts to ensure that it will receive hundreds of millions of doses if the tests are successful. The National Interest report indicates that there are a number of challenges to developing vaccines. The first is finding the vaccine, the second is producing it in sufficient quantities, and the third is giving people the vaccine

 

Comments Post Comment

Leave a Comment

Submit